CN116420877A - NMN, potassium, magnesium and selenium composition nutrition tablet and preparation method thereof - Google Patents
NMN, potassium, magnesium and selenium composition nutrition tablet and preparation method thereof Download PDFInfo
- Publication number
- CN116420877A CN116420877A CN202210963066.5A CN202210963066A CN116420877A CN 116420877 A CN116420877 A CN 116420877A CN 202210963066 A CN202210963066 A CN 202210963066A CN 116420877 A CN116420877 A CN 116420877A
- Authority
- CN
- China
- Prior art keywords
- nmn
- parts
- selenium
- magnesium
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 title claims abstract description 35
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 239000011669 selenium Substances 0.000 title claims abstract description 31
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 31
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 239000011591 potassium Substances 0.000 title claims abstract description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 239000011777 magnesium Substances 0.000 title claims abstract description 16
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 16
- 229910052700 potassium Inorganic materials 0.000 title claims abstract description 15
- 230000035764 nutrition Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 46
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 40
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 23
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 23
- 239000001103 potassium chloride Substances 0.000 claims abstract description 20
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- KMLRZZMUVYBQAH-UHFFFAOYSA-L [O-]S([O-])(=O)=O.OS(O)(=O)=O.[Mg+2].[SeH2] Chemical compound [O-]S([O-])(=O)=O.OS(O)(=O)=O.[Mg+2].[SeH2] KMLRZZMUVYBQAH-UHFFFAOYSA-L 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 25
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 17
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 17
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 15
- 235000015097 nutrients Nutrition 0.000 abstract description 11
- 230000032683 aging Effects 0.000 abstract description 10
- 230000003405 preventing effect Effects 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 7
- 210000002784 stomach Anatomy 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 210000000952 spleen Anatomy 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 235000011649 selenium Nutrition 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 238000007907 direct compression Methods 0.000 abstract description 2
- 150000002500 ions Chemical class 0.000 abstract description 2
- 238000000465 moulding Methods 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 13
- 230000001276 controlling effect Effects 0.000 description 7
- 229910001425 magnesium ion Inorganic materials 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 5
- 229910001414 potassium ion Inorganic materials 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 206010039921 Selenium deficiency Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- SWHAQEYMVUEVNF-UHFFFAOYSA-N magnesium potassium Chemical compound [Mg].[K] SWHAQEYMVUEVNF-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007105 physical stamina Effects 0.000 description 1
- 208000007645 potassium deficiency Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition nutrition tablet containing NMN, potassium, magnesium and selenium and a preparation method thereof, belonging to the technical field of health-care food preparation. The material is prepared from NMN, potassium chloride, magnesium sulfate, selenium, magnesium stearate, talcum powder, fructo-oligosaccharide and hydroxypropyl methylcellulose; according to the invention, NMN, potassium chloride, magnesium sulfate and selenium are effectively combined, the compatibility of the components is proper, the compatibility of the nutrient components of the composition is matched, the synergism is realized, the characteristics of simultaneous treatment of cardiovascular and cerebrovascular diseases, simultaneous nourishing of liver, kidney, spleen and stomach, combination of treatment and maintenance and the like are realized, and the effects of delaying aging and preventing and controlling the risks of cardiovascular and cerebrovascular diseases are achieved; has no influence on human body blood biochemistry and ions, good absorption effect, high bioavailability and no toxic or side effect, and can achieve the aim of simultaneously nourishing liver, kidney, spleen and stomach. The invention is characterized by direct compression molding of powder, simple production process, reduced production cost and convenient administration. Solves the problems that the NMN-containing products sold in the market at present are single in component and do not contain potassium chloride, magnesium sulfate and plant selenium.
Description
Technical Field
The invention relates to a composition oral nutritional tablet containing NMN, potassium chloride, magnesium sulfate and plant selenium and a preparation method thereof, belonging to the technical field of health-care food preparation.
Background
Life is precious for everyone, actively prevents and controls cardiovascular and cerebrovascular diseases, delays aging, is a great expectation for normal people and patients focusing on health, has health conditions related to element (Rong Yangsu) balance in each age range from life formation to life ending, and has four major diseases such as heart diseases, cerebrovascular accidents, diabetes mellitus, cancer and the like, which seriously threaten human life, and has also related to element balance regulation.
With the age, NMN in human body is reduced, electrolyte metabolism such as potassium and magnesium is disturbed, selenium deficiency is an important factor closely related to diseases such as cell activity decline, organ function weakening, pain growth promotion, cardiovascular and cerebrovascular diseases, arteriosclerosis and the like; therefore, supplementing the nutrients such as NMN, potassium, magnesium, selenium and the like has important significance for maintaining normal cellular metabolism of human body, improving cellular activity of human body, improving organ function of human body, preventing and controlling cardiovascular and cerebrovascular diseases risk, delaying aging and the like.
1. NMN is called B-nicotinic acid amine mononucleotide, belongs to vitamin B group derivative category, is a precursor substance of NAD+ (enzyme l), participates in cell energy generation, is closely related to DNA replication activity, has stronger enzyme activity, supplements and stabilizes NAD+ level in human body, recovers NAD+ balance of human body, can achieve the effects of delaying aging, improving heart aging and keeping cardiovascular and cerebrovascular health, has good prospect, is a new way for treating and preventing cardiovascular and cerebrovascular diseases at present, and has important clinical significance; therefore, the NMN supplementation can improve the energy metabolism of cells and increase the activity of the cells.
2. Potassium and magnesium ions are important electrolytes for maintaining normal life, the potassium ions in cells account for about 98 percent, the potassium ions in cells account for only 1-2 percent, normal human body needs to keep the concentration gradient, the biochemical process in the body can be normally carried out, the magnesium ions participate in the synthesis and metabolism of more than 300 enzymes, and the degraded Adenosine Diphosphate (ADP) can be converted into Adenosine Triphosphate (ATP); the electrolyte such as potassium and magnesium is supplied to the human body, so that the concentration of potassium and magnesium ions in cells can be improved, normal excitability, autonomy and conductivity of cardiac muscle cells can be maintained, normal excitation-contraction coupling of blood vessels and cardiac muscle cells can be maintained, and the potassium and magnesium ions play an important role in treating and improving cardiac functions and preventing and controlling cardiovascular and cerebrovascular diseases. Potassium chloride and magnesium sulfate are electrolytes that the human body must ingest exogenously, and their concentrations together determine the normal cell polarization state of the human body.
The NMN composition nutrition tablet is characterized in that whether magnesium sulfate can be absorbed by human body or not is proved by the composition according to the second regulation of the Chinese pharmacopoeia of 1995 edition and the discussion of the 16 th edition of new-compiled medicine, about 20% of magnesium sulfate is absorbed after being taken, and the composition magnesium sulfate is proved to be absorbed by human body in the nutrition tablet and can be added by application, so that the problem that oral magnesium sulfate is not easy to absorb is well explained, and the problem is basically consistent with the 100mg-300mg regulated by the country, and the table is shown below.
The table is derived from the "nutritional supplement claims and review rules" (trial) table with omissions.
3. Selenium is an important trace element required by human body, and because selenium element cannot be regenerated by human body and is mainly supplemented by exogenous food, the addition of selenium nutrient in NMN, potassium and magnesium composition can supplement and solve selenium deficiency condition of human body, raise oxidation resistance of human body, remove free radical of human body and raise immunity of human body, and has good health-care effect for effectively preventing angiocardiopathy and cerebrovascular disease, and has no toxic side effect for human body.
The NMN-containing products sold in the prior market are single in component, and do not contain potassium chloride, magnesium sulfate and plant selenium, including the prior published patent application documents, such as: publication number is CN109045158A, named as NMN-containing composition, and preparation method and application thereof; publication number "CN109170907a", entitled "a composition comprising NMN, use and method for preparing sports drink"; publication number "CN113559112a", entitled "preparation method and application of a composition containing NMN", etc.; the above-mentioned published patent applications contain NMN, and have certain energy supplementing and antifatigue effects, but have limited health care effects on human electrolyte disorder and cardiovascular and cerebrovascular diseases, because the contents of NMN and potassium chloride added in the composition are small, and the composition does not contain magnesium sulfate and selenium nutrients, and the pure supplementation of NMN nutrients but neglecting the supplementation of potassium magnesium ions and selenium or the smaller supplementation amount is incomplete for human effects, so that the normal metabolic needs of human bodies are difficult to meet. Therefore, when the NMN nutrient substances are sufficiently supplemented, potassium, magnesium ions and selenium are sufficiently supplemented, so that the purposes of preventing and controlling the risks of cardiovascular and cerebrovascular diseases, delaying aging and other many chronic diseases can be achieved.
A large number of animal experiments and clinical researches show that NMN is mainly located in cell nuclei, mitochondria and cytoplasm, myocardial cells possess a large number of mitochondria so as to provide energy requirements for contraction and relaxation in the whole life cycle, NMN can be obviously reduced in natural aging and diseases, magnesium is found to participate in all energy metabolism processes in an organism, mitochondria are power stations of cells, magnesium plays a non-negligible role in maintaining integrity of mitochondria, magnesium ion concentration in mitochondria is reduced, mitochondria can swell, magnesium deficiency and potassium deficiency are frequently combined, potassium magnesium is closely related to metabolism of mitochondria, mitochondrial function is reduced, cell activity is weakened, NMN, potassium, magnesium and selenium are supplemented, metabolic level of myocardial cells can be effectively improved, cardiac contraction capacity is improved, and cardiovascular and cerebrovascular accident risks are effectively reduced.
Disclosure of Invention
Aiming at the defects of the method for supplementing rare elements to human bodies, the invention provides a composition nutrition tablet for oral administration of NMN, potassium, magnesium and selenium and a preparation method thereof, wherein the composition nutrition tablet is simple in supplementing method and quick in human body absorption, and can achieve the purposes of maintaining normal cell energy metabolism of the human bodies, improving cell activity, recovering mitochondrial functions and improving microcirculation after being taken; so as to meet the physiological requirement of human body, and achieve the aims of delaying aging, reducing the occurrence of cardiovascular and cerebrovascular diseases, realizing the simultaneous treatment of cardiovascular and cerebrovascular diseases and the simultaneous nourishing of liver, kidney, spleen and stomach.
The invention realizes the aim through the following technical scheme:
a NMN, potassium, magnesium and selenium composite nutrition tablet is characterized by comprising the following raw materials in parts by weight,
NMN400 parts
300 parts of potassium chloride
200 parts of magnesium sulfate
Selenium 0.02 part
10 parts of magnesium stearate
Talcum powder 3.98 parts
80 parts of fructo-oligosaccharide
Hydroxypropyl methylcellulose 6 parts
The preparation process of the NMN, potassium, magnesium and selenium composite nutrition tablet is characterized by comprising the following steps:
(1) Weighing the raw materials according to the weight parts of the raw materials for standby;
(2) Drying potassium chloride in a drying oven for 10-30 minutes, wherein the temperature in the drying oven is controlled at 50-80 ℃;
(3) Drying magnesium sulfate in a vacuum drying oven at 60-90 deg.c and 0.8mPa for 10-30 min to eliminate partial crystal water, and cooling naturally to room temperature;
(4) Cooling potassium chloride and magnesium sulfate to room temperature, mixing with NMN raw powder, selenium, fructo-oligosaccharide, magnesium stearate, talcum powder and hydroxypropyl methylcellulose uniformly, pulverizing, and sieving with 100-300 mesh sieve;
(5) Feeding the crushed composition into a tablet press to prepare a nutritional tablet, drying the prepared nutritional tablet in a drying oven at 30-50 ℃ for 1-3 hours, taking out, and cooling to room temperature to obtain a nutritional tablet product;
(6) Packaging with packaging bottle or aluminum plastic bag to obtain the final product.
Compared with the prior art, the invention has the beneficial effects that:
(1) The invention realizes the simultaneous treatment of cardiovascular and cerebrovascular diseases, the simultaneous nourishing of liver, kidney, spleen and stomach, the combination of treatment and the like, can effectively meet the requirements of human bodies on the composition nutrition tablets, and achieves the aims of delaying aging and preventing and controlling the risks of cardiovascular and cerebrovascular diseases.
(2) The invention effectively combines NMN, potassium chloride, magnesium sulfate and selenium, has proper compatibility, proper compatibility of nutrient components of the composition, synergistic effect and no influence on human blood biochemistry and ions, accords with the theory of combining traditional Chinese medicine and modern medicine, has good absorption effect, high bioavailability and no toxic or side effect, and can achieve the aim of simultaneously nourishing liver, kidney, spleen and stomach.
(3) The invention is characterized by direct compression molding of powder and simple production process. The granulating process is omitted, so that energy sources can be saved, work efficiency is improved, production cost is reduced, and environmental pollution is avoided.
(4) The dosage form of the invention is an oral nutrient tablet, and is simple and convenient for healthy or unhealthy people to take, and can be taken intermittently or for a long time.
Detailed Description
(1) Weighing the following raw materials in parts by weight for later use;
400 parts of NMN, 300 parts of potassium chloride, 200 parts of magnesium sulfate, 0.02 part of selenium, 10 parts of magnesium stearate, 3.98 parts of talcum powder, 80 parts of fructo-oligosaccharide and 6 parts of hydroxypropyl methyl cellulose;
(2) Putting 300 parts of potassium chloride into a drying oven to be dried for 10 minutes, and controlling the temperature in the drying oven to be 80 ℃;
(3) Drying 200 parts of magnesium sulfate in a vacuum drying oven at 60 ℃ under the pressure of 0.8mPa for 30 minutes, removing part of crystal water, taking out, and naturally cooling to room temperature;
(4) After the potassium chloride and the magnesium sulfate are cooled to room temperature, the mixture is uniformly mixed with 400 parts of NMN raw powder, 0.02 part of selenium, 80 parts of fructo-oligosaccharides, 10 parts of magnesium stearate, 3.98 parts of talcum powder and 6 parts of hydroxypropyl methylcellulose, and then the mixture is crushed and sieved by a 300-mesh sieve;
(5) Feeding the crushed composition into a tablet press to prepare a nutritional tablet, drying the prepared nutritional tablet in a drying oven at 50 ℃ for 1 hour, taking out, and cooling to room temperature to obtain a nutritional tablet product;
(6) Packaging with packaging bottles or aluminum plastic bags, wherein 60 grains per bottle or bag is the nutrition tablet finished product.
To demonstrate the effect of taking a nutritional tablet of NMN, potassium, magnesium, selenium composition, the following experimental examples of its activity on mice are listed:
(1) Animal test, safety test:
the first two years of mice are 40, weight (20+ -2) g, and the nutrient tablets are fed according to the weight in two groups (the service life of the mice is less than three years, the mice of two years are equivalent to the age of 60-70 of human beings), and the mice are very old, and various physiological metabolism in the body is disturbed and the behavior is slow. Mice are divided into AB groups, 20 mice in each group are subjected to gastric lavage for 30-60 days, normal saline solution is filled into A groups every day, equivalent doses of NMN0.003 mg, potassium chloride 0.001 mg, magnesium sulfate 0.001 mg and selenium 0.0001 microgram are converted according to the body surface area ratio, the mice are fed with water normally and freely during the experiment, each of the mice is fed with water, water is used for drinking, the condition of stool and urine and whether poisoning is present or not is observed, no obvious behavior change and poisoning is observed in the two groups after the experiment is ended, the B groups of mice are observed to be very slim and also very active, different treatments are safe and nontoxic to take, no obvious side effect is found on the mice, no side effect is proved by short-term 30-day toxicity and long-term chronic toxicity, no obvious difference exists, the weight of each weighing experiment mice before and after the experiment is shown in the table below:
therefore, the nutritional tablet containing NMN, potassium chloride, magnesium sulfate, selenium and fructo-oligosaccharide is safe and nontoxic, has good anti-aging effect and obvious safety effect, and plays an important role in preventing and controlling cardiovascular and cerebrovascular diseases.
Animal test 2, physical ability test:
selecting healthy two-year-old mice for physical ability test, wherein the mice are divided into two groups AB, 20 mice in each group A are respectively filled with gastric physiological saline for 30 days, the equivalent dose of the mice in the test groups A is calculated to be NMN0.003 mg, potassium chloride 0.001 mg, magnesium sulfate 0.001 mg, selenium 0.0001 microgram and oligosaccharide 0.002 mg according to the body surface area ratio, the mice are continuously filled with stomach for 30 days in a laboratory, a load swimming test is carried out, lead skin with the weight of 3% is loaded at the tail part of the mice, the two groups are respectively put into 40cm deep water, swimming in a swimming box with the water temperature of 25 ℃ is observed, the two groups of mice respectively put into water are found to sink into water, wherein the time of sinking into water of the group A is the time of floating out of the water, and the time of sinking into water of the group B is the time of floating out of the water, and the results are shown in Table 2:
the load swimming experiment is an animal model for evaluating physical ability, and the water falling time and the swimming time are related to physical ability endurance. The method can reflect the physical stamina degree of old mice, in the test, after the B group mice are fed with the split dose of the nutrient tablets, the mice can be seen to be very slim and active, compared with the split dose of the A group physiological saline, the treatment of the A group can obviously prolong the water surface floating time of the mice in the load swimming and has obvious difference with the B group in time, so that the nutrient tablet composition containing NMN and the like has certain physical enhancement effect, obvious aging delay effect and important effect on preventing and controlling cardiovascular and cerebrovascular disease risks;
the above description is merely a preferred embodiment of the present invention, and the above illustration is not to be construed as limiting the spirit of the present invention in any way, and any simple modification or variation of the above embodiments according to the technical spirit of the present invention, and equivalent embodiments that may be changed or modified to equivalent variations using the above disclosed technical spirit of the present invention, will still fall within the scope of the technical solutions of the present invention, without departing from the spirit and scope of the present invention.
Claims (2)
1. A NMN, potassium, magnesium and selenium composite nutrition tablet is characterized by comprising the following raw materials in parts by weight,
NMN400 parts
300 parts of potassium chloride
200 parts of magnesium sulfate
Selenium 0.02 part
10 parts of magnesium stearate
Talcum powder 3.98 parts
80 parts of fructo-oligosaccharide
6 parts of hydroxypropyl methyl cellulose.
2. The preparation process of the NMN, potassium, magnesium and selenium composite nutrition tablet is characterized by comprising the following steps:
(1) Weighing the raw materials according to the weight parts of the raw materials for standby;
(2) Drying potassium chloride in a drying oven for 10-30 minutes, wherein the temperature in the drying oven is controlled at 50-80 ℃;
(3) Drying magnesium sulfate in a vacuum drying oven at 60-90 deg.c and 0.8mPa for 10-30 min to eliminate partial crystal water, and cooling naturally to room temperature;
(4) Cooling potassium chloride and magnesium sulfate to room temperature, mixing with NMN raw powder, selenium, fructo-oligosaccharide, magnesium stearate, talcum powder and hydroxypropyl methylcellulose uniformly, pulverizing, and sieving with 100-300 mesh sieve;
(5) Feeding the crushed composition into a tablet press to prepare a nutritional tablet, drying the prepared nutritional tablet in a drying oven at 30-50 ℃ for 1-3 hours, taking out, and cooling to room temperature to obtain a nutritional tablet product;
(6) Packaging with packaging bottle or aluminum plastic bag to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210963066.5A CN116420877A (en) | 2022-08-11 | 2022-08-11 | NMN, potassium, magnesium and selenium composition nutrition tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210963066.5A CN116420877A (en) | 2022-08-11 | 2022-08-11 | NMN, potassium, magnesium and selenium composition nutrition tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116420877A true CN116420877A (en) | 2023-07-14 |
Family
ID=87084262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210963066.5A Withdrawn CN116420877A (en) | 2022-08-11 | 2022-08-11 | NMN, potassium, magnesium and selenium composition nutrition tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116420877A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207294A (en) * | 1997-07-31 | 1999-02-10 | 谢理峰 | Potassium and magnesium controlled-release tablet and producing method thereof |
| CN101313741A (en) * | 2007-06-01 | 2008-12-03 | 顾安蓓 | Method of preparing novel composite aromatic condiment |
| CN103250829A (en) * | 2013-06-15 | 2013-08-21 | 郭志福 | Lotus plumule tea beverage |
| CN109170907A (en) * | 2018-08-30 | 2019-01-11 | 泓博元生命科技（深圳）有限公司 | A kind of preparation method of composition containing NMN, application and sports drink |
| CN112190601A (en) * | 2020-09-18 | 2021-01-08 | 北京健讯医药科技有限公司 | Tablet for improving memory, delaying aging and resisting oxidation and preparation method thereof |
-
2022
- 2022-08-11 CN CN202210963066.5A patent/CN116420877A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207294A (en) * | 1997-07-31 | 1999-02-10 | 谢理峰 | Potassium and magnesium controlled-release tablet and producing method thereof |
| CN101313741A (en) * | 2007-06-01 | 2008-12-03 | 顾安蓓 | Method of preparing novel composite aromatic condiment |
| CN103250829A (en) * | 2013-06-15 | 2013-08-21 | 郭志福 | Lotus plumule tea beverage |
| CN109170907A (en) * | 2018-08-30 | 2019-01-11 | 泓博元生命科技（深圳）有限公司 | A kind of preparation method of composition containing NMN, application and sports drink |
| CN112190601A (en) * | 2020-09-18 | 2021-01-08 | 北京健讯医药科技有限公司 | Tablet for improving memory, delaying aging and resisting oxidation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈文 等: "功能食品功效评价原料与动物实验方法", 中国质检出版社, pages: 57 - 59 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109452521B (en) | Auxiliary uric acid peptide reducing solid beverage, preparation method and application | |
| CN102793163A (en) | Calcium-iron-zinc-selenium multivitamin chewable tablet and preparation method thereof | |
| CN110338412A (en) | The composition and its preparation of niacinamide-containing mononucleotide and ice plant and application | |
| CN106107463A (en) | Super Quinoa Antifatigue milk tea processing technology | |
| CN108606269B (en) | Sports nutritional supplement and preparation method thereof | |
| CN105878397A (en) | Composition capable of regulating transportation stress of cattle and sheep | |
| CN102847159A (en) | A glucose metabolism enhancer | |
| CN102150838A (en) | Weight losing composition, preparation containing same and preparation method thereof | |
| CN108685971A (en) | A kind of Weight reducing compound and its preparation method and application | |
| CN107897875A (en) | It is a kind of to be used to improve Se-enriched yeast zinc metal sheet of sperm quality and vigor and preparation method thereof | |
| CN100998610A (en) | Antifatigue medicine contg. ombrophyte red chlorella | |
| CN112493485A (en) | NMN anti-aging health product and preparation method thereof | |
| CN116420877A (en) | NMN, potassium, magnesium and selenium composition nutrition tablet and preparation method thereof | |
| CN113826891A (en) | Composition containing compound vitamin and tabletting preparation method and application thereof | |
| CN108371709A (en) | Lycium ruthenicum tumor recovering gene enzyme | |
| CN101214052A (en) | Health food with physical energy fatigue alleviating and immunity reinforcing function | |
| CN113133500B (en) | Feed additive for relieving cow altitude disease, use method thereof and feed | |
| CN113615833A (en) | Mitochondrial nutrient composition for improving cardiovascular disease and application thereof | |
| CN1048400C (en) | Vitamin micro-element purine pyrimidine dinucleotide nutrient product and producing method | |
| CN102726731A (en) | Anti-radiation food and production technology thereof | |
| CN108323762B (en) | Selenium-rich composition and preparation, preparation method and application thereof | |
| CN111297821A (en) | Coenzyme Q10 capsule and preparation process thereof | |
| CN105831735A (en) | Quinoa infant super nutrient powder | |
| CN111493314A (en) | Food material nutrient with bioactive substances and solid beverage | |
| CN102114066B (en) | Medicinal composition for alleviating physical fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230714 |
|
| WW01 | Invention patent application withdrawn after publication |